Table 2.
Cohort | SNP ID | Chromosome / Position |
Gene | Location | Immune Measure |
N | Genotype | No. | Immune Response Outcome (IQR) |
P Value | Immune Measure |
N | Genotype | No. | Immune Response Outcome (IQR) |
P Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rubella Vaccine Study |
rs4682233 | 3/ 1.11×108 | PVRL3 | Intron | Secreted IL-6 (ng/µl) |
969 | AA AG GG |
953 16 0 |
3609.7 (3049.2, 4006.3) 3372.2 (1952.7, 4094.1) |
0.000675 | Secreted IFN-γ (ng/µl) |
969 | AA AG GG |
953 16 0 |
6.2 (1.5, 20.2) 3.7 (−5.8, 10.7) |
0.000498 |
Rubella Vaccine Study |
rs72935984 | 3/ 1.11×108 | PVRL3 | Intron | Secreted IL-6 (ng/µl) |
962 | CC CA AA |
944 18 0 |
3609.8 (3048.0, 4007.3) 3608.4 (2134.9, 4123.8) |
0.001363 | Secreted IFN-γ (ng/µl) |
962 | CC CA AA |
944 18 0 |
6.2 (1.5, 20.0) 5.4 (−0.4, 27.3) |
0.004264 |
Rubella Vaccine Study |
rs75054607 +NA |
3/ 1.11×108 | PVRL3 | Intron | Secreted IFN-γ (ng/µl) |
969 | AA AG GG |
946 22 1 |
6.1 (1.5, 19.7) 11.6 (3.9, 33.6) 508.8 (508.8, 508.8) |
0.000028 | NA (NT50) |
1029 | AA AG GG |
1004 23 2 |
56.6 (34.6, 93.9) 112.5 (65.5, 159.4) 192.1 (31.2, 353.0) |
0.001575 |
Rubella Vaccine Study |
rs76464851 +NA |
3/ 1.11×108 | PVRL3 | Intron | Secreted IFN-γ (ng/µl) |
969 | AA AG GG |
946 22 1 |
6.1 (1.5, 19.7) 11.6 (3.9, 33.6) 508.8 (508.8, 508.8) |
0.000028 | NA (NT50) |
1029 | AA AG GG |
1004 23 2 |
56.6 (34.6, 93.9) 112.5 (65.5, 159.4) 192.1 (31.2, 353.0) |
0.001575 |
Rubella Vaccine Study |
rs78157313 +NA |
3/ 1.11×108 | PVRL3 | Intron | Secreted IFN-γ (ng/µl) |
967 | AA AG GG |
944 22 1 |
6.1 (1.5, 19.8) 11.6 (3.9, 33.6) 508.8 (508.8, 508.8) |
0.000029 | NA (NT50) |
1027 | AA AG GG |
1002 23 2 |
56.6 (34.6, 93.8) 112.5 (65.5, 159.4) 192.1 (31.2, 353.0) |
0.001575 |
Rubella Vaccine Study |
rs72937914 +IFN-γ |
3/1.11 ×108 | PVRL3 | Intron | Secreted IL-6 (ng/µl) |
969 | AA AC CC |
942 27 0 |
3612.3 (3056.4, 4008.4) 2917.9 (2076.4, 4064.3) |
0.000386 | Secreted IFN-γ (ng/µl) |
969 | AA AC CC |
942 27 0 |
6.1 (1.5, 19.9) 6.1 (−0.4, 27.3) |
0.040073 |
Rubella Vaccine Study |
rs10433385 +IFN-γ |
3/1.11 ×108 | PVRL3 | Intergenic | Secreted IL-6 (ng/µl) |
968 | AA AG GG |
929 36 3 |
3613.2 (3056.4, 4020.6) 3398.5 (2754.5, 3870.5) 2717.6 (2617.3, 4306.3) |
0.008086 | Secreted IFN-γ (ng/µl) |
968 | AA AG GG |
929 36 3 |
6.3 (1.6, 20.8) 3.5 (0.1, 7.7) 3.4 (2.6, 16.6) |
0.012882 |
Rubella Vaccine Study |
rs78545860 +IFN-γ |
3/1.11×108 | PVRL3 | Intergenic | Secreted IL-6 (ng/µl) |
969 | AA AG GG |
930 36 3 |
3614.0 (3056.4, 4020.6) 3398.5 (2754.5, 3870.5) 2717.6 (2617.3, 4306.3) |
0.008063 | Secreted IFN-γ (ng/µl) |
969 | AA AG GG |
930 36 3 |
6.3 (1.6, 20.8) 3.5 (0.1, 7.7) 3.4 (2.6, 16.6) |
0.012874 |
Rubella Vaccine Study |
rs11820364 +NA |
11/1.2×108 | PVRL1 | Intron | Secreted IL-6 (ng/µl) |
969 | GG GA AA |
953 15 1 |
3595.6 (3036.5, 4000.4) 4328.9 (3759.0, 4494.6) 2271.6 (2271.6, 2271.6) |
0.000102 | NA (NT50) |
1029 | GG GA AA |
1010 18 1 |
57.4 (34.9, 95.3) 67.3 (32.5, 126.5) 75.8 (75.8, 75.8) |
0.00822 |
Rubella Vaccine Study |
rs61247604 | 11/1.2×108 | PVRL1 | Intron | Secreted IL-6 (ng/µl) |
968 | GG GA AA |
956 12 0 |
3596.0 (3037.7, 4003.1) 4178.1 (3605.9, 4384.3) |
0.000332 | NA (NT50) |
1028 | GG GA AA |
1015 13 0 |
57.4 (34.8, 95.8) 63.1 (36.2, 74.5) |
0.000477 |
Rubella Vaccine Study |
rs73571285* +IFN-γ |
11/1.2×108 | PVRL1 | Intron | Secreted IL-6 (ng/µl) |
969 | AA AG GG |
953 14 2 |
3600.2 (3049.7, 4003.7) 4011.0 (2630.3, 4439.8) −450.2 (−957.3, 56.9) |
0.000144 | Secreted IFN-γ (ng/µl) |
969 | AA AG GG |
953 14 2 |
6.2 (1.5, 20.0) 4.8 (−0.9, 62.3) −51.9 (−60.5, −43.3) |
0.022627 |
Rubella Vaccine Study |
rs73571287* +IFN-γ |
11/1.2×108 | PVRL1 | Intron | Secreted IL-6 (ng/µl) |
968 | GG GA AA |
959 8 1 |
3598.9 (3043.4, 4003.9) 4011.0 (1079.8, 4310.4) 56.9 (56.9, 56.9) |
9×10−7 | Secreted IFN-γ (ng/µl) |
968 | GG GA AA |
959 8 1 |
6.2 (1.5, 20.2) 3.7 (−1.1, 38.4) −43.3 (−43.3, −43.3) |
0.02229 |
Rubella Vaccine Study |
rs79849521 ++ |
11/1.2×108 | PVRL1 | Intron | Secreted IL-6 (ng/µl) |
969 | GG GA AA |
959 10 0 |
3598.9 (3036.5, 4003.9) 4099.9 (3356.6, 4328.9) |
0.026416 | NA (NT50) |
1029 | GG GA AA |
1018 11 0 |
57.4 (34.9, 95.7) 63.1 (33.4, 75.8) |
0.004395 |
Rubella Vaccine Study |
rs4936489 ++ |
11/1.2×108 | PVRL1 | Intergenic | Secreted IL-6 (ng/µl) |
968 | GG GA AA |
936 31 1 |
3605.0 (3041.1, 4005.1) 3514.8 (2803.7, 4126.2) 3696.9 (3696.9, 3696.9) |
0.042337 | NA (NT50) |
1028 | GG GA AA |
992 35 1 |
57.4 (34.7, 95.2) 65.5 (41.0, 101.3) 77.3 (77.3, 77.3) |
0.03046 |
Rubella Vaccine Study |
rs73578845+ NA |
11/1.19×108 | PVRL1 | Intergenic | Secreted IL-6 (ng/µl) |
969 | GG GC CC |
956 11 2 |
3596.0 (3041.1, 4003.1) 4078.1 (2299.1, 4439.8) 4099.9 (3970.0, 4229.9) |
0.000315 | NA (NT50) |
1029 | GG GC CC |
1015 12 2 |
57.4 (34.6, 95.4) 62.5 (52.7, 112.3) 116.5 (74.5, 158.6) |
0.037341 |
Rubella Vaccine Study |
rs2291842 +NA |
11/5719667 | TRIM2 2 |
Coding | Secreted IFN-γ (ng/µl) |
969 | AA AG GG |
639 285 45 |
5.9 (1.5, 19.9) 6.1 (1.9, 18.0) 11.5 (2.7, 42.5) |
0.014516 | NA (NT50) |
1029 | AA AG GG |
683 299 47 |
56.6 (34.6, 95.7) 58.9 (35.1, 94.8) 61.0 (34.9, 97.4) |
0.029181 |
Rubella Vaccine Study |
rs2291842 +NA |
11/5719667 | TRIM2 2 |
Coding | Secreted IL-6 (ng/µl) |
969 | AA AG GG |
639 285 45 |
3619.8 (3056.4, 4002.4) 3595.8 (3024.7, 4038.5) 3350.8 (3025.7, 3868.0) |
0.002321 | NA (NT50) |
1029 | AA AG GG |
683 299 47 |
56.6 (34.6, 95.7) 58.9 (35.1, 94.8) 61.0 (34.9, 97.4) |
0.029181 |
Rubella Vaccine Study |
rs2291842 +IFN-γ |
11/5719667 | TRIM2 2 |
Coding | Secreted IL-6 (ng/µl) |
969 | AA AG GG |
639 285 45 |
3619.8 (3056.4, 4002.4) 3595.8 (3024.7, 4038.5) 3350.8 (3025.7, 3868.0) |
0.002321 | Secreted IFN-γ (ng/µl) |
969 | AA AG GG |
639 285 45 |
5.9 (1.5, 19.9) 6.1 (1.3, 18.0) 11.5 (2.7, 42.5) |
0.014516 |
Rubella Vaccine Study |
rs962859~ +IFN-γ |
21/34648123 | IL10RB | Intron | Secreted IL-6 (ng/µl) |
954 | AA AC CC |
323 483 148 |
3660.3 (3064.3, 4061.3) 3569.1 (3023.7, 4000.9) 3533.8 (3066.0, 3900.4) |
0.008451 | Secreted IFN-γ (ng/µl) |
954 | AA AC CC |
323 483 148 |
6.9 (1.8, 22.8) 4.9 (1.2, 18.2) 7.5 (2.5, 21.4) |
0.027823 |
Rubella Vaccine Study |
rs2284552~ +IFN-γ |
21/34644082 | IL10RB | Intron | Secreted IL-6 (ng/µl) |
968 | CC CA AA |
600 321 47 |
3535.6 (2995.2, 3975.5) 3668.8 (3160.0, 4044.1) 3666.1 (3064.3, 4150.4) |
7.89×10−5 | Secreted IFN-γ (ng/µl) |
968 | CC CA AA |
600 321 47 |
5.9 (1.2, 19.2) 6.2 (1.9, 21.7) 7.9 (1.6, 30.7) |
0.018961 |
Rubella Vaccine Study |
rs5030728 ++ |
9/1.2×108 | TLR4 | Intron | Secreted IL-6 (ng/µl) |
965 | GG GA AA |
489 398 78 |
3619.4 (3066.3, 4016.0) 3597.3 (3015.3, 3984.0) 3569.5 (2943.2, 4033.6) |
0.018059 | Secreted IFN-γ (ng/µl) |
965 | GG GA AA |
489 398 78 |
5.5 (0.8, 19.7) 6.4 (1.9, 20.0) 6.5 (1.4, 25.2) |
0.037292 |
Rubella Vaccine Study |
rs2770150 +IFN-γ |
9/1.2×108 | TLR4 | Intergenic | Secreted IL-6 (ng/µl) |
968 | AA AG GG |
516 389 63 |
3615.4 (3064.5, 4005.1) 3600.2 (3018.3, 4008.4) 3542.9 (2943.2, 4085.3) |
0.01256 | Secreted IFN-γ (ng/µl) |
968 | AA AG GG |
516 389 63 |
5.9 (1.1, 20.0) 6.3 (1.7, 19.2) 6.6 (1.1, 27.5) |
0.017476 |
Rubella Vaccine Study |
seq- rs112723153 +IFN-γ |
19/45178636 | PVR | Intron | Secreted IL-6 (ng/µl) |
969 | GG GA AA |
961 8 0 |
3609.8 (3049.2, 4008.4) 2936.2 (2438.8, 3855.6) |
0.011401 | Secreted IFN-γ (ng/µl) |
969 | GG GA AA |
961 8 0 |
6.1 (1.5, 20.0) 10.4 (0.3, 34.5) |
0.041896 |
Rubella Vaccine Study |
rs2229857~ +IFN-γ |
1/1.55 ×108 | ADAR | Coding | Secreted IL-6 (ng/µl) |
968 | GG GA AA |
505 374 89 |
3595.6 (3058.5, 4006.3) 3594.7 (3036.5, 4033.3) 3732.8 (3023.6, 3969.3) |
0.000435 | Secreted IFN-γ (ng/µl) |
968 | GG GA AA |
505 374 89 |
6.0 (1.4, 20.0) 5.9 (1.5, 19.2) 8.4 (2.3, 22.1) |
0.01358 |
Rubella Vaccine Study |
rs3870968 +IFN-γ |
6/29647149 | ZFP57 | Intron | Secreted IL-6 (ng/µl) |
969 | CC CA AA |
866 102 1 |
3619.6 (3038.9, 4024.9) 3523.0 (3032.0, 3900.6) 3643.5 (3643.5, 3643.5) |
0.006571 | Secreted IFN-γ (ng/µl) |
969 | CC CA AA |
866 102 1 |
5.9 (1.3, 19.2) 9.0 (3.2, 38.2) 16.1 (16.1, 16.1) |
0.018177 |
Rubella Vaccine Study |
rs469483~ +IFN-γ |
21/42818515 | MX1 | Intron | Secreted IL-6 (ng/µl) |
969 | AA AG GG |
308 485 176 |
3528.1 (2975.4, 3968.9) 3641.8 (3064.3, 4080.6) 3598.0 (3096.5, 3975.8) |
0.002902 | Secreted IFN-γ (ng/µl) |
969 | AA AG GG |
308 485 176 |
5.0 (0.9, 18.5) 6.6 (1.8, 21.8) 6.4 (1.6, 19.5) |
0.019999 |
Rubella Vaccine Study |
rs2393657 ++ |
6/26457688 | BTN2A 1/BTN3 A3 |
Intergenic | Secreted IL-6 (ng/µl) |
961 | CC CA AA | 854 107 0 |
3619.9 (3064.3, 4023.2) 3398.9 (2750.9, 3832.4) |
0.031523 | Secreted IFN-γ (ng/µl) |
961 | CC CA AA |
854 107 0 |
6.2 (1.6, 20.8) 6.1 (0.4, 15.2) |
0.034371 |
Abbreviations: NA-neutralizing antibody; SNP ID-single nucleotide polymorphism identification; IL-interleukin; IFN-interferon; IQR-interquartile range; NT50-neutralizing titer; A-Adenine; C-Cytosine; G-Guanine; No.-number
Negative values indicate that the unstimulated secretion levels were higher than the rubella virus-stimulated secretion levels.
Loss of significant association when homozygous minor allele genotype (observed only in few subjects) was excluded from analysis
+One phenotype failed to remain significantly associated with genotype as determined by having a q-value greater than 0.1.
++Two phenotypes failed to remain significantly associated with genotype as determined by having a q-value greater than 0.1.
~IL-6 remained significantly associated with genotype as determined by having a q-value greater than 0.1 in the Caucasian subset.